Chinese Journal of Oncology 2014;36(11):858-862
Clinicopathological features and prognostic analysis of 151 patients with primary extra-nodal non-Hodgkin's lymphoma.
Cong WANG 1 ; Changji YUAN 1 ; Hua HE 1 ; Ou BAI 2 3
Affiliations
Country
China
Language
Chinese
MeSH
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
ACTIONS
Abstract
OBJECTIVETo evaluate the epidermiology, clinicopathological features and prognosis of primary extra-nodal non-Hodgkin's lymphoma (PE-NHL).
METHODSThe clinicopathological data of 151 patients diagnosed as PE-NHL in the First Affiliated Hospital of Jilin University between January 2007 and December 2011 were reviewed and analyzed.
RESULTSThe proportion of PE-NHL patients was 58.8% among all the non-Hodgkin's lymphoma cases, with the average age of 52 years, and the male/female ratio was 1.16:1. The most frequently involved site was the stomach (30.5%) followed by nose and sinuses (19.9%) and Waldeyer's ring (17.2%). The most common subtype was diffuse large B-cell lymphoma (DLBCL) (55.0%), followed by NK/T (18.5%) and extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) ( 13.2%). The distribution of clinical stages was as follows: stage I 20.5%, II 29.8%, III 29.1%, and IV 20.5%. Most nasal PE-NHL is in early stages, with a proportion of 76.7% in stages I & II. The 3-year overall survival rate was 73.2% and 3-year progression free survival rate was 46.6% in the PE-DLBCL patients. The International Prognosis Index (IPI) could be used to estimate the prognosis of PE-DLBCL well. Multivariate analysis showed that ESR and curative effect of the first treatment were independent prognostic factors for PE-DLBCL patients.
CONCLUSIONSThe incidence of PE-NHL is quite high, and the most common primary extra-nodal site is the gastro-intestinal tract and the most common subtype is diffuse large B-cell lymphoma. Risk groups based on IPI can indicate the prognosis of PE-DLBCL to some extent, but only the ESR and curative effect of the first treatment are confirmed to be independent risk factors.
备案号: 11010502037788, 京ICP备10218182号-8)